News
MaxCyte, Inc. - Final Results for Year Ended 31 December 2017
·Revenues increased 14% to $14.0 million. ·Investment in CARMA™ was $7.5 million as the Company prepared and completed the filing of its first investigational new drug application with the US Food and Drug Administration. ·Operating expenses increased to $21.8 million in 2017.
·Revenues increased 14% to $14.0 million. ·Investment in CARMA™ was $7.5 million as the Company prepared and completed the filing of its first investigational new drug application with the US Food and Drug Administration. ·Operating expenses increased to $21.8 million in 2017.